The validity of XPO1 as a therapeutic target for MM was confirmed in a number of reports, including genome-wide studies [144], and led to the discovery and eventual approval of the orally effective XPO1 blocker selinexor (Xpovio) (Figure 6B) for the treatment of MM. This evidence concerns the gene XPO1 and Miyoshi myopathy.